Respiratory syncytial virus vaccine development

Published on June 24, 2015   43 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

0:00
I'm Peter Openshaw. I'm the Professor of Experimental Medicine at Imperial College London. And I've been working on Respiratory Syncytial Virus for more years than I care to remember, actually, since about 1985. And what I'm going to do today is to summarize some of the most important background about RSV, talk a bit about animal models for vaccine development, and then the current vaccines that are under development, and where I think the vaccine field is going in the future.
0:31
So first a bit about Respiratory Syncytial Virus. It was first named the Chimpanzee Coryza Agent by a group that had been studying chimps and found that some of the chimp handlers had common colds and that the chimps had common colds, too. It was subsequently renamed, Respiratory Syncytial Virus by Bob Chanock, but I think that the name is a very regrettable one. I think that if instead it had been called, the "Savage Agent," the whole history of RSV research would have been changed. I've been trying to get the name changed to the Savage Agent, but nobody seems to take this very seriously.
Hide

Respiratory syncytial virus vaccine development

Embed in course/own notes